Photodynamic Therapy for Ulcerative Colitis
NCT01697670 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7
Last updated 2012-11-05
Summary
Objectives:
Primary: The primary study objective is to determine a clinical response as assessed by the Mayo score to low dose PDT in patients with moderate to severe active distal UC.
Secondary: The secondary study objectives are to assess the effect on inflammation and the safety and tolerability of low dose PDT in patients with moderate to severe active distal UC.
This is a multicenter, open phase II study that will enroll a maximum of 20 eligible patients with moderate to severe active distal UC. The first 10 eligible patients, the first cohort, will receive PDT at a 10 Joule per square centimetre (J/cm2) dose intensity. If no clinical response is observed in the first 7 eligible patients, the study will be stopped due to lack of efficacy. If at least 1 clinical response is observed in the first 7 patients, the first cohort will be completed to a total of 10 eligible patients
* Trial with medicinal product
Conditions
Interventions
- DRUG
-
Photodynamic therapy with Gliolan
Laser light illumination with red light at 635 nm using a cylindrical light diffuser (Model RD, Medlight SA) in a white diffusing inflatable balloon catheter (model CDB OEB, Medlight SA) at a fluence rate of 65.5 mW/cm2 over 153 s resulting in a total light dose of 10 J/cm2 is performed 3 hours after administration of 15mg/kg bodyweight Gliolan
Sponsors & Collaborators
-
Swiss National Science Foundation
collaborator OTHER -
University of Zurich
lead OTHER
Principal Investigators
-
Marianne Ortner, MD · University Hospital Zurich, Division Gastroenterology
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-09-30
- Primary Completion
- 2012-12-31
- Completion
- 2012-12-31
Countries
- Switzerland
Study Locations
More Related Trials
-
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis
NCT02762500 ·Status: COMPLETED ·Phase: PHASE2
-
Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study
NCT01567956 ·Status: TERMINATED ·Phase: PHASE3
-
A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis
NCT03844932 ·Status: TERMINATED ·Phase: PHASE2
-
Low Dose IL-2 for Ulcerative Colitis
NCT02200445 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety Study of Ozanimod in Ulcerative Colitis
NCT01647516 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis
NCT02337608 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis
NCT01434576 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
NCT02163759 ·Status: COMPLETED ·Phase: PHASE3
-
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
NCT05702879 ·Status: RECRUITING
-
Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis
NCT03934216 ·Status: COMPLETED ·Phase: PHASE2
-
Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis
NCT01294410 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.
NCT03675477 ·Status: COMPLETED ·Phase: PHASE2
-
Propionyl-L-Carnitine in Ulcerative Colitis
NCT01026857 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis
NCT01149707 ·Status: COMPLETED ·Phase: PHASE2
-
Real-world Data Regarding Treatment of Ulcerative Colitis Patients With Golimumab
NCT03394586 ·Status: UNKNOWN
-
Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis
NCT01829321 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis
NCT05907330 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)
NCT01562314 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
NCT04996797 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness of Golimumab in Patients With Ulcerative Colitis: Results of a Real-life Study in Switzerland
NCT05405465 ·Status: COMPLETED
-
Generate Real World Data On Tofacitinib Induction Therapy and Changes In Clinical and Patient Reported Outcomes.
NCT05069259 ·Status: TERMINATED
-
Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares
NCT03494764 ·Status: COMPLETED ·Phase: PHASE2
-
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
NCT04209556 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis
NCT02277470 ·Status: UNKNOWN
-
Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis
NCT02895100 ·Status: TERMINATED ·Phase: PHASE2